跳轉至內容
Merck
全部照片(1)

重要文件

SML0064

Sigma-Aldrich

MBX-102

≥98% (HPLC)

同義詞:

(aR)-4-Chloro-a-[3-(trifluoromethyl)phenoxy]benzeneacetic acid 2-(acetylamino)ethyl ester, Arhalofenate, JNJ39659100, MBX-102/JNJ39659100

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C19H17ClF3NO4
CAS號碼:
24136-23-0
分子量：:
415.79
分類程式碼代碼:
12352200
NACRES:
NA.77

品質等級

100

化驗

≥98% (HPLC)

形狀

powder

顏色

white to tan

溶解度

DMSO: ≥35 mg/mL

起源

Johnson & Johnson

儲存溫度

2-8°C

InChI

1S/C19H17ClF3NO4/c1-12(25)24-9-10-27-18(26)17(13-5-7-15(20)8-6-13)28-16-4-2-3-14(11-16)19(21,22)23/h2-8,11,17H,9-10H2,1H3,(H,24,25)/t17-/m1/s1

InChI 密鑰

BJBCSGQLZQGGIQ-QGZVFWFLSA-N

應用

MBX-102 may be used in PPAR-mediated cell signaling studies.

生化／生理作用

MBX-102 has a potent transrepression effect on PPARγ. It is an oral glucose-reducing agent and also has insulin-sensitizing properties. It is useful as treatment for type 2 diabetes. MBX-102 also lowers triglycerides in a PPARα-independent manner.
MBX-102 is a selective PPAR modulator (SPPARM) and has been shown to inhibit phosphorylation of PPARγ. MBX-102 is converted to the active form, MBX-102 acid, in vivo.

特點和優勢

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Nuclear Receptors (Non-Steroids) and Nuclear Receptors (PPARs) pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形圖

Skull and crossbonesEnvironment
GHS06,GHS09

訊號詞

Danger

危險聲明

H301,H319,H400

危險分類

Acute Tox. 3 Oral - Aquatic Acute 1 - Eye Irrit. 2

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number
061M4615V

未看到正確版本？

如果您需要一個特定的版本，您可以透過批號來尋找特定憑證。

搜尋 COA

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Francine M Gregoire et al.
Molecular endocrinology (Baltimore, Md.), 23(7), 975-988 (2009-04-25)
MBX-102/JNJ39659100 (MBX-102) is in clinical development as an oral glucose-lowering agent for the treatment of type 2 diabetes. MBX-102 is a nonthiazolidinedione (TZD) selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-gamma that is differentiated from the TZDs structurally, mechanistically, preclinically
Apurva Chandalia et al.
PPAR research, 2009, 706852-706852 (2009-05-01)
MBX-102/JNJ-39659100 (MBX-102) is a selective, partial PPAR-γ agonist that lowers glucose in the absence of some of the side effects, such as weight gain and edema, that are observed with the TZDs. Interestingly MBX-102 also displays pronounced triglyceride lowering in

文章

Nuclear Receptors (PPARs)

Peroxisome proliferator activated receptors (PPARs) are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors that are related to retinoid, steroid and thyroid hormone receptors.

Nuclear Receptors (Non-Steroids)

We offer many products related to non-steroid nuclear receptors for your research needs.

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務